Opportunisitic yeasts: Candida albicans, Candida tropcialis, Candida glabrata, Cryptococcus neoformans, Candida krusei (variable activity)
Opportunistic hyaline moulds: Scedosporium spp. (variable activity)
Dimorphic moulds: Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Parracoccidioides brasiliensis, Sporothrix schenkii, Penicillium marneffei
Dematiaceous moulds: variable activity
Inhibition of 14-a-demethlyase blocks formation of ergosterol and leads to the buildup of toxic methylated 14-a-sterols and depletes ergosterol in the cell membrane.
Other azoles have shown in murine models to exhibit AUC:MIC ratio as predictive of effect for Candida species. This may vary by fungal species however.
Tmax: 1-4 hours; Cmax:3-5mcg/ml; Vd: 1.16 L/Kg; Total Clearance: 2.75 ml/min/Kg; Table 2
Gastrointestinal: nausea, vomiting, abdominal pain, anorexia
Skin and appendages pruritus, rash, potentially exfoliative
Liver and biliary system: Elevation of hepatic transaminases (<10%), hepatitis
Endocrine: adrenal insufficiency, decreased testosterone synthesis, menstrual irregularities
Special senses: photophobia
Nervous System: headache
Cream, topical: 2% (15g, 30g, 60g)
Shampoo, topical: 1% (6mL, 120 mL, 210mL)
Tablet: 200 mg
Mucosal infections/cutaneous infection: 200 mg/day for 2 weeks
Extensive mucosal infection/recalcitrant dermatophyte infections: 400 mg/day for 4 weeks
Systemic mycoses: 400 mg/day for 6-12 months
Shampoo: Apply twice weekly for 4 weeks with at least 3 days between each shampoo.
Topical: Rub gently into the affected area once daily to twice daily.
Renal failure: Dose adjustment is unnecessary in patients with altered renal function.
Hepatic failure: Dose adjustment is unnecessary in patients with moderate hepatic dysfunction.
Contraindications: hypersensitivity to ketoconazole; CNS fungal infections (due to poor CNS penetration); coadministration with ergot derivatives, astemizole, or cisapride is contraindicated due to risk of potentially fatal cardiac arrhythmias
Ketoconazole is a potent inhibitor of the cytochrome P450 3A4 isoenzyme system. Caution should be exercised and monitoring is suggested when concomitantly administering ketoconazole with drugs that have narrow therapeutic windows and are substrates of the CYP3A4 substrates.
Category C: Risk unknown. Human studies inadequate.
Liver function tests should be monitored throughout treatment.
Several brand names/manufacturers (Click here for list)